News

Biomarkers provide insights into sinus rhythm in atrial fibrillation

New research presented at the ESC Congress 2023 revealed that specific blood markers can help accurately predict the return of sinus rhythm in patients with atrial fibrillation. These discoveries may significantly enhance treatment strategies.

The image shows a red heart model next to a stethoscope on a light-coloured, blurred surface. Blurred ECG lines can be seen in the background, indicating a medical environment. It symbolises the connection between heart health and medical diagnostics.
Copyright: Adobe Stock/ AmazingArt

The EAST-AFNET 4 study identified key biomarkers, including ANGPT2, BMP10, and NT-proBNP, which play a vital role in predicting the likelihood of sinus rhythm restoration. NT-proBNP, in particular, showed strong connections to prior treatments and could be used to develop personalized therapies. Patients with lower levels of these biomarkers had a much higher probability of achieving a normal heart rhythm after treatment.

These findings, presented at the ESC Congress, could transform the treatment of atrial fibrillation by enabling doctors to identify high-risk patients early. This would allow for more personalized, intensive treatment approaches, ultimately improving long-term therapy success. With this knowledge, therapies can be tailored to individual patient needs, offering optimized monitoring and more precise treatments.

International research collaborations underscore the potential of biomarkers in enhancing atrial fibrillation care and reducing the risk of relapse, paving the way for a more targeted and effective approach to treating this condition.


The text is an shortened version of an AFNET press release.